The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data.
Julien Taïeb
Consultant or Advisory Role - Merck KGaA
Honoraria - Merck KGaA
Tim Maughan
Honoraria - Merck KGaA
Carsten Bokemeyer
Consultant or Advisory Role - Merck KGaA
Honoraria - Merck KGaA
Research Funding - Merck KGaA
Eric Van Cutsem
Consultant or Advisory Role - Merck KGaA
Research Funding - Merck KGaA
Thomas Brodowicz
Honoraria - Merck KGaA
Gunnar Folprecht
Consultant or Advisory Role - Bristol-Myers Squibb; Merck KGaA; Roche
Honoraria - Merck KGaA; Novartis; Pfizer; Roche
Research Funding - Merck KGaA
Regina Esser
Employment or Leadership Position - Merck KGaA
Stock Ownership - Merck KGaA
Michael Schlichting
Employment or Leadership Position - Merck KGaA
Josep Tabernero
Consultant or Advisory Role - Amgen; Merck KGaA; Roche; Sanofi